NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Biotechnology · USD

Alto Neuroscience, Inc. (ANRO) Stock Analysis

Alto Neuroscience, Inc. (ANRO) is a Biotechnology stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

ANRO

$23.32

−$1.09 (−4.47%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ANRO with… →

ANRO Key Statistics

As of Oct 21, 2026
Trading
Open
$24.74
Previous Close
$24.41
Day's Range
23.28–25.01
52-Week Range
9.73–37.48
Volume
663.46K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.34
Valuation
Market Cap
$915.13M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.31
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$63.24M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
39.24M
1-Year Return
+114.93%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
549.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ANRO closed at $23.32, +114.93% over 1 year.

Alto Neuroscience, Inc. (ANRO) has a market capitalization of $915.13M.

In fiscal 2025, ANRO reported revenue of $0.00.

ANRO Stock Return by Calendar Year

Alto Neuroscience, Inc. (ANRO) return since Feb 2024: what $10,000 became

1 year
$10,000 $21,493
+114.93%
Since Feb 2024
$10,000 $11,266
+12.66%

If you had invested $10,000 in Alto Neuroscience, Inc. (ANRO) at the close on February 2, 2024, the earliest close on record here, it would have been worth $11,266 at the close on October 21, 2026: +12.66% in total, +4.49% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+31.01%
2025+320.80%
2024 (partial year)−79.57%

As of October 21, 2026.

ANRO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$63.24M—
2024$0.00−$61.43M—
2023$0.00−$36.31M—
2022$0.00−$27.71M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$66.36M−$63.24M—
2024$0.00—−$68.61M−$61.43M—
2023$0.00—−$37.81M−$36.31M—
2022$0.00—−$27.46M−$27.71M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Alto Neuroscience, Inc. (ANRO) at $915.13M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 68.

The most recent close on file for ANRO is $23.32, dated October 21, 2026. That is −$1.09 (−4.47%) against the previous close. The 52-week range on file runs from $9.73 to $37.48. The latest close sits 139.67% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $63.24M. Earnings per share on a trailing basis come to −2.31.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is +114.93%. The stored price history starts on February 2, 2024, and the total return since then is +12.66%. The reported beta is 1.34. Annualized volatility over the trailing 2 years is 117.69%.

Growth & Income

No dividend is on file for ANRO.

2026 is still running; the total return is +31.01% year to date. The record holds one complete calendar year, 2025, which returned +320.80%.

Peer Comparison

Alto Neuroscience, Inc. (ANRO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Alto Neuroscience, Inc. ANRO $915.13M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Alto Neuroscience, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Visit website →